April 4, 2022
Adaptive Phage Therapeutics Extends Series B to $61 million with Addition of The AMR Action Fund | Business Wire
GAITHERSBURG, Md.--(BUSINESS WIRE)--Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company dedicated to providing therapies…
